Viewing Study NCT06740656


Ignite Creation Date: 2025-12-24 @ 11:18 PM
Ignite Modification Date: 2025-12-25 @ 8:59 PM
Study NCT ID: NCT06740656
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-02-18
First Post: 2024-12-08
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Neuromuscular Complications of MEK Inhibitors: a French Case Series and a Systematic Review of the Literature
Sponsor: Central Hospital, Nancy, France
Organization:

Study Overview

Official Title: Neuromuscular Complications of MEK Inhibitors: a French Case Series and a Systematic Review of the Literature
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: MEK inhibitors (trametinib, cobimetinib, selumetinib or binimetinib) have been used since 2016 to treat metastatic melanoma, by targeting the MAPK pathway Neuromuscular complications (neuropathy, myasthenia or myositis) have been reported in patients treated with MEK inhibitors.

With the growing use of these new oncology therapies, neurologists, oncologists and other clinicians are likely to be increasingly confronted with MEK inhibitor-induced neuropathy, myasthenia or myositis.

Yet, so far, these complications have only been documented in a few single case reports.

Our aim was to characterize the neuromuscular complications associated with MEK inhibitors used either alone or in combination.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: